Leerink lowered the firm’s price target on Voyager Therapeutics (VYGR) to $11 from $12 and keeps an Outperform rating on the shares. Voyager Therapeutics reported Q3 results and provided pipeline updates, highlighting progress in Alzheimer’s programs and its NeuroShuttle nonviral delivery platform, and the company remains on track for key milestones in 2026, including PET imaging data for VY7523 and an IND filing for siRNA therapy VY1706, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VYGR:
- Voyager Therapeutics reports Q3 EPS (47c), consensus (52c)
- Voyager Therapeutics expects cash to fund operations into 2028
- Voyager Therapeutics, Transition Bio entered into drug discovery collab
- Voyager Therapeutics Advances Alzheimer’s Study with VY7523
- Voyager Therapeutics: Strategic Positioning and Regulatory Endorsements Drive Buy Rating